<p>Long Noncoding RNA DLGAP1-AS1 Promotes the Aggressive Behavior of Gastric Cancer by Acting as a ceRNA for microRNA-628-5p and Raising Astrocyte Elevated Gene 1 Expression</p>

Abstract

Purpose: The long noncoding RNA DLGAP1 antisense RNA 1 (DLGAP1-AS1) plays welldefined roles in the malignant progression of hepatocellular carcinoma. The purpose of this study was to determine whether DLGAP1-AS1 affects the aggressive behavior of gastric cancer (GC). Methods: DLGAP1-AS1 expression in GC tissue samples and cell lines was determined by reverse-transcription quantitative PCR. GC cell proliferation, apoptosis, migration, invasion, and tumor growth in vitro as well as in vivo were examined by the Cell Counting Kit-8 assay, flow-cytometric analysis, transwell migration and invasion assays, and xenograft model experiments, respectively. Results: DLGAP1-AS1 was overexpressed in GC tissue samples and cell lines. Among patients with GC, the increased level of DLGAP1-AS1 correlated with tumor size, TNM stage, lymph node metastasis, distant metastasis, and shorter overall survival. The knockdown of DLGAP1-AS1 suppressed GC cell proliferation, migration, and invasion in vitro, as well as promoted cell apoptosis and hindered tumor growth in vivo. Mechanistically, DLGAP1-AS1 functioned as a competing endogenous RNA for microRNA-628-5p (miR-628-5p) in GC cells, thereby increasing the expression of the miR-628-5p target astrocyte elevated gene 1 (AEG-1). Functionally, the recovery of the miR-628-5p/AEG-1 axis output attenuated the effects of DLGAP1-AS1 knockdown in GC cells. Conclusion: DLGAP1-AS1 is a pleiotropic oncogenic lncRNA in GC. DLGAP1-AS1 plays a pivotal part in the oncogenicity of GC in vitro and in vivo by regulating the miR-628-5p/ AEG-1 axis. DLGAP1-AS1, miR-628-5p, and AEG-1 form a regulatory pathway to facilitate GC progression, suggesting this pathway as an effective target for the treatment of GC.

Long non-coding RNA DLGAP1-AS1 promotes the progression of gastric cancer via miR-515-5p/MARK4 axis

“…The present work proved that DLGAP1-AS1 was an oncogenic lncRNA in GC, which indicated it could be a promising biomarker and therapy target. Interestingly, our results are in agreement with a recent study that reported that the increased expression of DLGAP1-AS1 in GC tissues correlates with tumor size, TNM stage, lymph node metastasis, distant metastasis, and poor prognosis of the patients (19). lncRNA acts as a competitive endogenous RNA (ceRNA), so-called molecular sponge, to interact with miRNA and inhibit miRNA expression to reduce the miRNA repressive effect on targeting mRNA (20).…”

LINC00514 promotes gastric cancer cell growth and EMT progression via miR-204-3p/KRAS

“…Li et al [ 38 ] noted that IGF2-AS enhanced GC cell invasion, growth and migration by regulating miR-937/EZH2. Deng et al [ 39 ] showed that DLGAP1-AS1 induced GC progression by sponging miR-628-5p/AEG-1. Liu et al [ 40 ] noted that SNHG1 induced GC cell EMT progression via modulation of the DCLK1/miR-15b/Notch1 axis.…”

The lncRNA DLGAP1-AS1/miR-149-5p/TGFB2 axis contributes to colorectal cancer progression and 5-FU resistance by regulating smad2 pathway

“…Deng et al. 25 reported that DLGAP1-AS1 promotes the aggressive behavior of gastric cancer by acting as a ceRNA for miRNA-628-5p and raising astrocyte-elevated gene 1 expression. Functional analyses showed that proliferation and invasion potency were decreased while apoptosis rate was increased in HT-29 and SW480 cells after DLGAP1-AS1 expression was silenced.…”